Gurjeet Kahlon’s Post

Earlier this afternoon we heard from Curtis Mo, DLA Piper Partner, and Scott Kupor, Andreessen Horowitz Managing Partner, on the state of venture capital in 2024. Follow #DLAPiperTechSummit2024 to get the latest insights from our Global Tech Summit. #VentureCapital #TechLaw

Earlier this afternoon we heard from Curtis Mo, DLA Piper Partner, and Scott Kupor, Andreessen Horowitz Managing Partner, on the state of venture capital in 2024. Follow #DLAPiperTechSummit2024 to get the latest insights from our Global Tech Summit. #VentureCapital #TechLaw

“At GV, anyone can bring forward an idea and explore it.” GV’s Tom Hulme sat down with Harry Stebbings’ 20VC to talk about: 🌟 Creating great cultures 🔨 Advice for founders on fundraising and company-building 💡 Insights from decades in venture capital 📱 Portfolio companies including Nothing, Synthesia, and more. Watch the full conversation — https://bit.ly/3WsL1CH

🚀 First steps towards creating a network of VC investors in deep-tech! 🌟 🌍 The European Commission has taken the initial steps to establish a network of European venture capital investors ready to invest alongside the EIC fund in innovative European deep-tech companies. 💪 The goal is to enhance collaboration and distribute risks among deep-tech investors. 🚀 In 2023, the EIC was the most active European investor in deep-tech. 📈 For every € invested by the EIC fund, an additional €3.8 was attracted from venture capital funds, corporations, and other investors. More information 👉 https://shorturl.at/nGKju #deeptech #innovation #investments #EIC

🚀 Exciting Resource Alert for Venture Capital Enthusiasts!🌟 I'm thrilled to share a comprehensive glossary that's a must-read for anyone navigating the complex world of venture capital transactions. Whether you're a founder, investor, or just curious about the VC landscape, this document is packed with essential terms and insights to guide you through. 🔍 Highlights Include: - Accelerators & Angel Investors: Unpack the roles and impacts of key players in the startup ecosystem. - Financial Instruments: A deep dive into SAFE agreements, convertible notes, and more. - Investor Rights & Exit Strategies: Understand the nuances of what investors look for and how exit scenarios are navigated. This glossary is more than just definitions; it's a roadmap to understanding the intricacies of venture capital investments, from funding rounds to IPOs. Let's demystify venture capital together! 🌐 #HanySewilam #VentureCapital #StartupFunding #InvestmentTerms #InnovationEcosystem

While funding has dipped from the $21B high seen in 2021, VCs continue to launch money into space tech companies. 🚀 In August alone, venture capitalists invested well over $100M in the space, focusing primarily on companies at the Pre-Seed, Seed, and Series A stages. Want to know which segments are seeing cosmic returns and which are financial black holes (so far)? Read our Space Tech PE Playbook here: https://hubs.la/Q02PSfxD0 #venturecapital #privateequity #spacetech #investmenttrends

The State of #VentureCapital in 2024 What does 2024 have in store for venture GPs and LPs? Join Juniper Square live on Thursday, March 21st, along with a panel of VC industry experts Sean Park, Jeff B., Kelli Fontaine & Eugene Tetlow as they discuss: → What it will take for venture investments to start trending upward; → What key issues are top of mind for VC LPs, and; → Where the biggest opportunities in venture capital in 2024 might be. Sign up ⇓

Great quarter to be in SD Biotech: "In San Diego, startup funding for the second quarter surpassed $1 billion for the fifth consecutive year, driven by dozens of tech and life science venture capital fundings. San Diego saw roughly 42 deals in Q2 including four startups raising $100+ million, known as mega-deals." Top five largest bio deals: Endeavor BioMedicines: a Solana Beach-based biotech raised $132 million Alterome Therapeutics, Inc: an early-stage biotech raised $132 million. Enlaza Therapeutics: a La Jolla-based company raised $100 million. Bright Peak Therapeutics: a Del Mar-based biotech raised $90 million. Aardvark Therapeutics: a UTC-based biotech raised $85 million.

Simple advice from GV: 1. Unfair advantage 2. Power of context 3. Risk paranoia

Dive into an insightful discussion with Sumita Banerjee, Director, Insights & Strategic Initiatives, and Thomas Park, Leading Partner, Deep Tech Venture Fund, as they chat with Michael Curran from the Ottawa Business Journal. Discover how BDC is empowering the Canadian #VC and #Tech ecosystem, some emerging trends in the Ottawa VC market, and get an update on our $200M Deep Tech Venture Fund focused on transformative technologies.   #TechopiaLIVE #CDNTech #VentureCapital #DTVFund #DeepTech   https://lnkd.in/efKDZAmc